{
    "pmcid": "9181070",
    "qa_pairs": {
        "How do the single domain antibodies demonstrate suitability for therapeutic applications?": [
            "They retain structural integrity and functionality under various pH and temperature conditions",
            "They are easily degraded by host enzymes",
            "They require refrigeration for stability",
            "They lose efficacy in acidic environments"
        ],
        "What is the role of the receptor binding domain (RBD) in the SARS-CoV-2 spike protein?": [
            "Binding to the ACE2 receptor on host cells",
            "Facilitating membrane fusion",
            "Stabilizing the spike protein structure",
            "Initiating viral RNA replication"
        ],
        "What potential advantage do the single domain antibodies offer for antiviral strategies?": [
            "Targeting conserved polybasic sites for broad-spectrum antiviral strategies",
            "Inducing rapid viral mutation to prevent resistance",
            "Enhancing viral replication to outcompete other viruses",
            "Blocking host immune responses to reduce inflammation"
        ],
        "What specific site on the SARS-CoV-2 spike protein do the single domain antibodies target to interfere with proteolytic processing?": [
            "Polybasic cleavage site (CSP)",
            "N-terminal domain (NTD)",
            "Fusion peptide (FP)",
            "Transmembrane domain (TM)"
        ],
        "Which unrelated viruses were cross-neutralized by the anti-CSP single domain antibodies?": [
            "Herpes simplex virus 1 (HSV1) and pestes des petits ruminants virus (PPRV)",
            "Influenza A virus and Zika virus",
            "Ebola virus and Marburg virus",
            "Hepatitis C virus and Dengue virus"
        ]
    }
}